Clinical Trial Update: APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL) [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/Phase 2 trial of APR-246 in combination with acalabrutinib or venetoclax in relapsed/refractory non-Hodgkin lymphoma has been terminated with results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Mantle Cell Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• APR-246 (eprenetapopt)
• Acalabrutinib (acalabrutinib)
• Venetoclax (venetoclax)

Snippet

Sponsor: Aprea Therapeutics | Conditions: Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2024-11-15